ClinicalTrials.gg
CompletedNCT06435221ORCA-OLUpdated Nov 26, 2025

Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers

A Phase 3 interventional study of Cytisinicline in Smoking Cessation and Vaping Cessation, sponsored by Achieve Life Sciences. Completed at 29 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Achieve Life Sciences · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
479
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing cytisine in Smoking Cessation — 3 open to participants now, 5 under way, 1 of them phase 3. cytisine · Smoking Cessation.

Enrollment
9th of 22
479 · median 202
Started
2024
with 2 others
Phase 3
7 of 22
none open now
Registered
19th of 22
by date
Lead sponsor
10 of 22
Achieve Life Sciences

Among the 22 studies testing cytisine in Smoking Cessation, this one is the 9th largest by enrollment, is one of 3 that started in 2024, is one of 7 in phase 3, and was the 19th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

3 of the 22 studies testing cytisine in Smoking Cessation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cytisine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing cytisine in Smoking Cessation, or all of them as a file.
02

Study summary

Safety assessment of long-term 3 mg cytisinicline three times daily (TID) exposure for 52 weeks is the main purpose of this study, conducted in the United States.

03

Conditions studied

  • Smoking Cessation
  • Vaping Cessation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Prior participation in the ORCA-2, ORCA-3 or ORCA-V1 clinical studies.
  2. Former ORCA-2/ORCA-3 and ORCA-V1 subjects who are current daily cigarette smokers and/or daily nicotine-containing electronic cigarette users. Amount of daily combustible and/or nicotine containing electronic cigarette use at baseline is determined by subject self-report.
  3. At Screening, subjects must have expired carbon monoxide (CO) ≥10 ppm if self-reporting as smokers or ≥30 ng/mL cotinine using a point-of-care cotinine oral fluid screening device if self-reporting as users of nicotine containing electronic cigarettes.
  4. Willing to initiate cytisinicline treatment on the day after enrollment and set a quit date within 14 days of starting treatment.
  5. Willing to actively participate in the study's cessation behavioral support provided throughout the study.
  6. Able to fully understand study requirements, willing to participate, and comply with dosing schedule.
  7. Sign the Form.

Exclusion criteria

Exclusion Criteria:

  1. Known to cytisinicline or any of the .
  2. abnormal screening serum chemistry or hematology values.
  3. Clinically significant abnormal screening 12-lead determined after minimum of 5 minutes in supine position (ie, requiring treatment or further assessment).
  4. Recent history (within 3 months prior to screening) of acute myocardial infarction, unstable angina, stroke, cerebrovascular incident or hospitalization for congestive heart failure.
  5. Current uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg).
  6. Currently psychotic or having had a psychotic event within 3 months prior to screening; currently having suicidal ideation or risk for suicide (corresponding to question 4 or 5 on the screening C-SSRS OR "Yes" to any suicidal behavior question on the screening C-SSRS with clear suicidal intent or previous attempt); or current symptoms of moderate to severe depression (depression score ≥11 on the HADS) at screening. If any subject becomes psychotic during the study, they must be removed from cytisinicline treatment and/or additional study visits.
  7. Severe renal impairment defined as a (CrCl) \<60 mL/min on screening lab (estimated with the Cockroft-Gault equation).
  8. Hepatic impairment defined as (ALT) or aspartate aminotransferase (AST) >2.0 x the (ULN) on screening lab.
  9. Women who are pregnant or breast-feeding.
  10. Female subjects of who do not agree to use acceptable methods of during the study. Acceptable methods of birth control include:

    • True abstinence: When this is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception].
    • Barrier methods:

      • diaphragm
      • cervical cap
      • contraceptive sponge
    • Hormonal methods:

      • Oral contraceptives
      • Vaginal ring such as NuvaRing
      • Skin patch such as Xulane
      • Injection such as Depro-Provera
      • Implantable rod such as Nexplanon
  11. Participation in a clinical study with an drug in the 4 weeks prior to enrollment.
  12. Any other reason that the investigator views the subject should not participate or would be unable to fulfill the requirements for the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
479 participants (actual)

Study arms

  • Experimental
    Cytisinicline 3 mg TID

    Cytisinicline 3 mg TID for 52 weeks.

    Drug: Cytisinicline

Interventions

  • film-coated oral tablets containing 3 mg cytisinicline

    Also known as: Cytisine

06

What researchers measure

Primary outcomes

  1. Incidence Rate of Treatment Emergent Serious Adverse Events (SAEs)

    Time frame: up to Week 52

Secondary outcomes

  1. Incidence Rate of Related Treatment Emergent SAEs

    Time frame: up to Week 52

  2. Incidence Rate of Treatment Emergent Adverse Events (TEAEs)

    Time frame: up to Week 52

  3. Incidence Rate of Related TEAEs

    Time frame: up to Week 52

  4. Number of Participants With Clinically Significant Abnormal Hematology and Chemistry Parameters

    Time frame: up to Week 52

  5. Percentage of Participants With Clinically Significant Abnormal Hematology and Chemistry Parameters

    Time frame: up to Week 52

  6. Number of Participants With Potentially Clinically Significant Abnormal Vital Signs

    Time frame: up to Week 52

  7. Percentage of Participants With Potentially Clinically Significant Abnormal Vital Signs

    Time frame: up to Week 52

07

Study locations

29 sites
  • Alliance for Multispecialty Research, LLC
    Mobile, Alabama 36608, United States
  • Alliance for Multispecialty Research, LLC
    Tempe, Arizona 85281, United States
  • Little Rock Allergy & Asthma Clinical Research Center
    Little Rock, Arkansas 72205, United States
  • Alliance for Multispecialty Research, LLC
    Coral Gables, Florida 33134, United States
  • Accel Research Sites Network - DeLand Clinical Research Unit
    DeLand, Florida 32720, United States
  • Alliance for Multispecialty Research, LLC
    Fort Myers, Florida 33912, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Precision Clinical Research
    Sunrise, Florida 33351, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • Alliance for Multispecialty Research, LLC
    Oak Brook, Illinois 60523, United States
  • MediSphere Medical Research Center, LLC
    Evansville, Indiana 47714, United States
  • Alliance for Multispecialty Research, LLC
    Wichita, Kansas 67207, United States
  • Alliance for Multispecialty Research, LLC
    Lexington, Kentucky 40509, United States
  • Alliance for Multispecialty Research, LLC
    New Orleans, Louisiana 70119, United States
  • Massachusetts General Hospital - Clinical Genetic Facility
    Boston, Massachusetts 02114, United States
  • Insight Research Institute
    Flint, Michigan 48507, United States
  • Alliance for Multispecialty Research, LLC
    Kansas City, Missouri 64114, United States
  • Alliance for Multispecialty Research, LLC
    Las Vegas, Nevada 89119, United States
  • Global Medical Institutes LLC; Princeton Medical Institute
    Princeton, New Jersey 08540, United States
  • Rochester Clinical Research, LLC
    Rochester, New York 14609, United States
  • Centricity Research Columbus Ohio Multispecialty
    Columbus, Ohio 43213, United States
  • Alliance for Multispecialty Research, LLC
    Norman, Oklahoma 73069, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405, United States
  • Alliance for Multispecialty Research, LLC
    Knoxville, Tennessee 37909, United States
  • Clinical Research Associates, Inc.
    Nashville, Tennessee 37203, United States
  • Clinical Trials of Texas, LLC
    San Antonio, Texas 78229, United States
  • Health Research of Hampton Roads, Inc.
    Newport News, Virginia 23606, United States
  • Alliance for Multispecialty Research, LLC
    Norfolk, Virginia 23502, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Sep 2025, 16 months.

Of 31 phase 3 interventional studies under Smoking Cessation, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 60. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2024
First posted
May 30, 2024
StartActual
May 28, 2024
Primary completionActual
Sep 29, 2025
CompletionActual
Oct 6, 2025
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06435221
Responsible party
Sponsor
First posted
May 30, 2024
Start date
May 28, 2024
Primary completion
Sep 29, 2025
Completion
Oct 6, 2025
Last update
Nov 26, 2025

Study contacts

Julie Ball
study director · Achieve Life Sciences, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cytisine

Start the discussion